Stay updated on FirstLine Trabectedin, Ipilimumab, Nivolumab Clinical Trial
Sign up to get notified when there's something new on the FirstLine Trabectedin, Ipilimumab, Nivolumab Clinical Trial page.

Latest updates to the FirstLine Trabectedin, Ipilimumab, Nivolumab Clinical Trial page
- Check3 days agoChange DetectedFooter revision updated from v3.3.3 to v3.3.4; no modifications to core study content, eligibility criteria, contact information, locations, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedA new Locations section now lists Santa Monica, California as a study site. The old California Locations block and the HHS Vulnerability Disclosure link were removed, and the revision tag updated to v3.3.3.SummaryDifference0.2%

- Check47 days agoChange DetectedRevision label updated from v3.3.1 to v3.3.2 in the page footer.SummaryDifference0.1%

- Check54 days agoChange DetectedThe page footer now shows Revision: v3.3.1 instead of v3.2.0. This change does not affect the study details or any information presented on the page.SummaryDifference0.1%

- Check61 days agoChange DetectedRemoved a government funding/operating status notice from the bottom of the page; no trial data, enrollment details, or navigation elements were altered. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check75 days agoChange DetectedNo notable changes detected; the page content and layout appear unchanged.SummaryDifference0.4%

Stay in the know with updates to FirstLine Trabectedin, Ipilimumab, Nivolumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the FirstLine Trabectedin, Ipilimumab, Nivolumab Clinical Trial page.